Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/36370
Title: | Associations of medications with lower odds of typical COVID-19 symptoms : cross-sectional symptom surveillance study |
Author(s): | Urbach, Dietmar Awiszus, Friedemann Leiß, Sven Venton, Tamsin Specht, Alexander Vincent Apfelbacher, Christian |
Issue Date: | 2020 |
Type: | Article |
Language: | English |
URN: | urn:nbn:de:gbv:ma9:1-1981185920-366025 |
Subjects: | COVID-19 SARS-CoV-2 Statins Antihypertensives Surveillance Hydroxymethyl-glutaryl-coenzyme A reductase inhibitors |
Abstract: | Background: As the COVID-19 pandemic continues to spread across the globe, the search for an effective medication to treat the symptoms of COVID-19 continues as well. It would be desirable to identify a medication that is already in use for another condition and whose side effect profile and safety data are already known and approved. Objective: The objective of this study was to evaluate the effect of different medications on typical COVID-19 symptoms by using data from an online surveillance survey. Methods: Between early April and late-July 2020, a total of 3654 individuals in Lower Saxony, Germany, participated in an online symptom-tracking survey conducted through the app covid-nein-danke.de. The questionnaire comprised items on typical COVID-19 symptoms, age range, gender, employment in patient-facing healthcare, housing status, postal code, previous illnesses, permanent medication, vaccination status, results of reverse transcription polymerase chain reaction (RT-PCR) and antibody tests for COVID-19 diagnosis, and consequent COVID-19 treatment if applicable. Odds ratio estimates with corresponding 95% CIs were computed for each medication and symptom by using logistic regression models. Results: Data analysis suggested a statistically significant inverse relationship between typical COVID-19 symptoms self-reported by the participants and self-reported statin therapy and, to a lesser extent, antihypertensive therapy. When COVID-19 diagnosis was based on restrictive symptom criteria (ie, presence of 4 out of 7 symptoms) or a positive RT-PCR test, a statistically significant association was found solely for statins (odds ratio 0.28, 95% CI 0.1-0.78). Conclusions: Individuals taking statin medication are more likely to have asymptomatic COVID-19, in which case they may be at an increased risk of transmitting the disease unknowingly. We suggest that the results of this study be incorporated into symptoms-based surveillance and decision-making protocols in regard to COVID-19 management. Whether statin therapy has a beneficial effect in combating COVID-19 cannot be deduced based on our findings and should be investigated by further study. |
URI: | https://opendata.uni-halle.de//handle/1981185920/36602 http://dx.doi.org/10.25673/36370 |
Open Access: | Open access publication |
License: | (CC BY 4.0) Creative Commons Attribution 4.0 |
Sponsor/Funder: | DFG-Publikationsfonds 2020 |
Journal Title: | JMIR public health and surveillance |
Publisher: | JMIR Publications |
Publisher Place: | Toronto |
Volume: | 6 |
Issue: | 4 |
Original Publication: | 10.2196/22521 |
Page Start: | 1 |
Page End: | 10 |
Appears in Collections: | Medizinische Fakultät (OA) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Urbach et al._Associations_2020.pdf | Zweitveröffentlichung | 117.91 kB | Adobe PDF | View/Open |